TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02250651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham: Applicator Without Needle
Description: Sham administered on Day 1, Week 16, and Week 32.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham: Applicator Without Needle
Description: Sham administered on Day 1, Week 16, and Week 32.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham: Applicator Without Needle
Description: Sham administered on Day 1, Week 16, and Week 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator: Timolol 0.5%
Description: Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator: Timolol 0.5%
Description: Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Timolol 0.5%
Description: Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle (placebo)
Description: Timolol vehicle administered once in the morning and once in the evening for up to 20 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle (placebo)
Description: Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
Study: NCT04560426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative parathyroid gland auxiliary recognition system
Description: The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
Study: NCT04188808

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bypass surgery
Description: All patients scheduled for elective surgery of PAA and PAD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Description: All patients scheduled for elective surgery of PAA and PAD.
Study: NCT01536249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Single Oral Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine plus Dexpramipexole
Description: Multiple Oral Doses
Study: NCT03837405

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Description: Education for carbohydrate-restricted diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfuless
Description: Mindful eating app use plus group sessions to learn mindfulness
Study: NCT00360490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone acetate
Description: Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
Study: NCT01085669

Intervention type: DEVICE
Intervention: Microbiological analysis of retained VEPTR Implants
Description: Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
Study: NCT00726895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: 1 x 324 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: 2 x 324 mg capsules
Study: NCT02269150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation (FMT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No fecal microbiota transplantation (FMT), routine management
Study: NCT03115073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candiplus
Description: Administration of Candiplus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candiplus
Description: Administration of Candiplus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candiplus
Description: Administration of Candiplus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Administration of Clotrimazole
Study: NCT01837550

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: The control group only had access to reading material.
Study: NCT01722643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAxIM
Description: This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
Study: NCT04000893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise session
Description: Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
Study: NCT02303119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab IV
Description: intra-venous, 375 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab IV
Description: intra-venous, 375 mg/m²
Study: NCT01913054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate Fat Emulsion Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Injection
Study: NCT00381849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystone
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystone
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cystone
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill (Placebo)
Description: Participants will take 2 pills, 2 times a day for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (Placebo)
Description: Participants will take 2 pills, 2 times a day for 6 weeks.
Study: NCT03755739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Description: vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
Study: NCT02303119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: sub-cutaneous, 1400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab SC
Description: sub-cutaneous, 1400 mg
Study: NCT00448864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecallantide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecallantide
Study: NCT03755739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Description: vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
Study: NCT01928537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib sodium
Study: NCT02808611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Reduction of the ANS response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01810172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital pleural drainage system
Description: Reusable device with disposable collection system for digital monitoring of air leak.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry suction pleura drainage device
Description: Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
Study: NCT04373551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultural adaptation of a patient-provider communication tool
Description: Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
Study: NCT00448864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04881513

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Narrow Band Imaging
Description: Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tongue sensitivity testing
Description: testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
Study: NCT00247039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solgar Israel
Description: Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: placebo capsules
Study: NCT01545310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354
Description: One dose of ABT-354
Study: NCT03847012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
Study: NCT01338597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic thyroidectomy
Description: endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic thyroidectomy
Description: endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
Study: NCT03060265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Administrating Paracetamol IV pre-cesarean section

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Administrating SALINE IV pre-cesarean section
Study: NCT01884623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT03303014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 Prolene, 5-0 Fast Absorbing Gut
Description: The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5-0 Prolene, 5-0 Fast Absorbing Gut
Description: The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
Study: NCT04881513

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitiy of life
Description: Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Threshold change
Description: Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Taste
Description: Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
Study: NCT02911935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral azithromycin
Description: Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
Study: NCT03815916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Study: NCT01981161

Intervention type: PROCEDURE
Intervention: biological samples and clinical data
Study: NCT01200524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 50 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06499181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: The primary objective is to examine differences in post-operative opioid consumption between the two groups.
Study: NCT02911935

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension
Study: NCT02650973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-1701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT01723917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoSERM tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoSERM tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00570206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
Study: NCT03930069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
Study: NCT02270034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is added to Stupp method
Study: NCT02464670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered IM followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4202
Description: INO-4202 delivered IM followed by Electroporation
Study: NCT06499181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
Study: NCT02464670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered ID followed by Electroporation
Study: NCT00000373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olanzapine + fluoxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo + fluoxetine
Study: NCT02464670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered ID followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered ID followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered ID followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered ID followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201
Description: INO-4201 delivered ID followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4212
Description: INO-4212 delivered IM followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4212 + INO-9012
Description: INO-4212 + INO-9012 delivered IM followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201 + INO-9012
Description: INO-4201 + INO-9012 delivered ID followed by Electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201 + INO-9012
Description: INO-4201 + INO-9012 delivered ID followed by Electroporation
Study: NCT01413412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair using full thickness skin graft
Description: 25 patients
Study: NCT02464670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-4201 + INO-9012
Description: INO-4201 + INO-9012 delivered ID followed by Electroporation